Quantcast

Industry news that matters to you.  Learn more

Assurex Health Releases Enhanced Pharmacogenomic Test to Help Clinicians Select Medications for Depression, Anxiety and PTSD

Assurex Health recently announced an enhancement of its GeneSight® Psychotropic test, providing clinicians with the most comprehensive genetic-based tool available to help them make individualized antidepressant and antipsychotic medication decisions for patients with depression, anxiety, post-traumatic stress disorder (PTSD), bipolar disorder, schizophrenia and other behavioral health disorders. GeneSight Psychotropic now covers 38 FDA-approved medications, including recently approved levomilnacipran (Fetzima®) and vortioxetine (Brintellix®).

Genomind Releases Statement Supporting NIMH Announcement to Move Away from DSM Categories

Genomind, a personalized medicine company, has released a statement in response to the National Institute of Mental Health’s (NIMH) announcement by Director Dr. Thomas Insel that the organization will be re-orienting its research away from DSM categories, supporting the move and its potential to influence improved treatment of patients with mental disorders.

DSM (Diagnostic and Statistical Manual of Mental Disorders) is a psychiatric diagnostics system based upon patient-reported symptoms that are used to define succinct syndromes and make medication choices. While the system has been in place for decades, it has not taken into consideration patient etiology or pathophysiology.

The remedy proposed by NIMH is the Research Domain Criteria (RDoC) Project, which would alter procedures to include genetics, imaging, cognitive science, and other specific endophenotypes which reflect specific changes in the brain associated with psychiatric conditions, creating a fuller understanding of both a patient’s disorder and how to best address treatment.

Genomind believes that the use of biomarkers in psychiatry can only help improve patient care. Better knowledge of a patient’s genetics can lead to better medication choices by reducing adverse drug side effects, which are based upon genetic impairments in drug metabolism. Continued research and focus on biomarkers may also help the industry understand underlying pathophysiological changes in the brain that lead to psychiatric disorders.

“The core of Genomind’s philosophy is that psychiatric disorders are dimensional, not categorical, and NIMH’s position directly supports this,” says Dr. Jay Lombard, Genomind’s Chief Scientific Officer and Medical Director. “We hope this move by the NIMH and the resulting RDoC Project will not only allow patients to receive more personalized, tailored care, but help the mental health community gain greater insight into how we can improve treatment even further in the future.”

Genomind is committed to discovery of the underlying causes of neuropsychiatric disorders and supports the development of personalized medicine that improves patients’ lives. The company’s core product is the GeneceptTM Assay, a comprehensive, simple-to-use tool for understanding genetic and biological markers that best inform response to different psychiatric treatments including depression, bipolar disorder, schizophrenia, anxiety disorders, autism and ADHD.

Source: Genomind

Using Biomarkers to Identify and Treat Schizophrenia

In the current online issue of PLoS ONE, researchers at the University of California, San Diego School of Medicine say they have identified a set of laboratory-based biomarkers that can be useful for understanding brain-based abnormalities in schizophrenia. The measurements, known as endophenotypes, could ultimately be a boon to clinicians who sometimes struggle to recognize and treat the complex and confounding mental disorder.

Enhanced Biomarker Test Aids Clinicians With Difficult to Treat Psychiatric Disorders

Genomind recently announced enhancements to its Genecept™ Assay, a proprietary biomarker test and analytic report, which helps inform treatment options in neuropsychiatry. The enhancements include adding three new genes to its panel, a redesigned report, and an upgraded technical platform.

Lundbeck Canada Donates $2.7 Million to Fund Ground-breaking Depression Research

Lundbeck Canada has made a landmark donation of $2.7 million to support ground-breaking research at the University Health Network to identify biomarkers (biological markers) that will enhance the diagnosis and treatment of patients suffering from major depression and bipolar disorder.